NCT04577963 2025-07-14
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT06471673 2024-08-26
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
Phase 1/2 Recruiting
NCT06547476 2024-08-09
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting
NCT04734262 2023-11-18
SPARK
Fudan University
Phase 2 Unknown
NCT05861635 2023-05-17
The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4 Unknown